Xalatan, Latanoprost News

Abel Pharmboy is the nom de plume of an academic researcher and educator who took his PhD in Pharmacology and Therapeutics and BS in Toxicology.

Novel Drug has Potential to Create Significant Improvement in Function of Diseased Tissue BRIDGEWATER, N.J. & RESEARCH TRIANGLE PARK, N.C.-- --Oct 22, 2009 - Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its ...

In May 2001, I suddenly developed an irregular heart rate. It would sometimes go two or three beats and then miss one.

Dear Dr. Gott: In May 2001, I suddenly developed an irregular heart rate. It would sometimes go two or three beats and then miss one.

Intravitreal bevacizumab has been associated with significant early functional and anatomic improvements in macular edema.

With the increasing number of people participating in physical aerobic exercise, jogging in particular, we considered that it would be worth knowing if there are should be limits to the exercise with regard to the intraocular pressure of the eyes.

There are few good indications to whether Allergan 's Latisse could also cure male-pattern baldness.

Sophia Antipolis, France, August 6, 2009. . www.nicox.com -- NicOx S.A. today announced the signature of an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207 , which has completed two phase 2 studies in patients with primary open angle glaucoma and ocular hypertension.

Sophia Antipolis, France, August 6, 2009. . www.nicox.com -- NicOx S.A. today announced the signature of an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207 , which has completed two phase 2 studies in patients with primary open angle glaucoma and ocular hypertension.

Almost a full year after Pfizer Inc. decided to discontinue development of PF-03187207, it finally handed the compound back to its erstwhile partner, NiCox SA, and has withdrawn from its strategic alliance in ophthalmology with the company.

Sophia Antipolis, France, August 6, 2009. . www.nicox.com -- NicOx S.A. today announced the signature of an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207 , which has completed two phase 2 studies in patients with primary open angle glaucoma and ocular hypertension.

Should these popular drugs be stopped for cataract surgery? And if so, when should they be restarted? Because glaucoma is a chronic con- dition affecting primarily the elderly, many of these patients develop visually significant cataracts under our care.